LORAZEPAM TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

LORAZEPAM

Verfügbar ab:

SIVEM PHARMACEUTICALS ULC

ATC-Code:

N05BA06

INN (Internationale Bezeichnung):

LORAZEPAM

Dosierung:

2MG

Darreichungsform:

TABLET

Zusammensetzung:

LORAZEPAM 2MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/1000

Verschreibungstyp:

Targeted (CDSA IV)

Therapiebereich:

BENZODIAZEPINES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0110731002; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2016-09-08

Fachinformation

PRODUCT MONOGRAPH
LORAZEPAM
LORAZEPAM TABLETS USP
0.5 MG, 1 MG AND 2 MG
ANXIOLYTIC-SEDATIVE
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUÉBEC
H4R 2P7
DATE OF PREPARATION: AUGUST 20, 2014
CONTROL NO. : 176952
Lorazepam Product Monograph
Page 2 of 24
TABLE OF CONTENTS
PRESCRIBING INFORMATION
.............................................................................................
1
ACTIONS AND CLINICAL PHARMACOLOGY
.......................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
6
CONTRAINDICATIONS
..........................................................................................................
6
WARNINGS
...........................................................................................................................
6
PRECAUTIONS
......................................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
9
ADVERSE REACTIONS
.......................................................................................................
10
SYMPTOMS AND TREATMENT OF OVERDOSE
............................................................... 11
DOSAGE AND ADMINISTRATION
.......................................................................................
11
AVAILABILITY OF DOSAGE FORMS
..................................................................................
12
PHARMACEUTICAL INFORMATION
...................................................................................
13
PHARMACOLOGY................................................................................................................
14
TOXICOLOGY.......................................................................................................................
16
REFERENCES
.................................................